Raynaud’s phenomenon is a condition in which there is an exaggerated blood vessel tightening in response to cold or emotional stress, restricting blood flow to certain areas of the body – most often the fingers, but sometimes the toes, ears, or the end of the nose.
The exaggerated vascular response (tightening) in Raynaud’s phenomenon is called vasospasm, which often occur in response to cold or emotional stress. With vasospasm, the fingers turn white and cold then blue with dilated veins followed by relaxation of the vessel and normal blood flow causing a red ‘flushing’
According to a recent article published in The New England Journal of Medicine, Raynaud’s affects approximately 3 to 5 percent of the population – women are more often affected than men. Raynaud’s phenomenon occurs in two forms – primary and secondary. Primary is the most common and has no underlying cause. Secondary is when Raynaud’s phenomenon occurs in combination with another autoimmune disease like scleroderma, rheumatoid arthritis, Sjogren’s syndrome or systemic lupus erythematous. The article also states that people who work with certain chemicals, like vinyl chloride, or vibrating tools like a jackhammer are also susceptible to secondary Raynaud’s. Continue reading →
Do you have rheumatoid arthritis, ankylosing spondylitis or polyarticular juvenile idiopathic arthritis or care for someone who does? We need your valuable input.
Health Canada defines biosimilars (sometimes referred to as subsequent entry biologics or SEBs) as biologic medicines that are similar to, and would enter the market after, an approved originator biologic (such as Enbrel®).
Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. Biosimilars are not identical to their originator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, biosimilars may have unique efficacy, immunogenicity, and safety profiles that are different from their originator.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar etanercept for the treatment of rheumatoid arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis. The originator biologic, or reference product, is etanercept (Enbrel®). Continue reading →
MedPage Today interviewed specialists in rheumatology in the United States about the advances in rheumatology in 2016. Below are the five most common advances mentioned.
1. Tocilizumab (Actemra) for the treatment of giant cell arteritis
Giant cell arteritis affects over 200,000 people in the United States. Research data from an international clinical trial showed that after a year of treatment, 56% of the 250 study participants given tocilizumab weekly plus prednisone were in sustained remission, compared with just 14% of those given placebo alone (P<0.0001).
At the annual meeting of the American College of Rheumatology (ACR), Dr. John H. Stone of Harvard University at Boston noted: “There is something new in giant cell arteritis at last, and the era of unending glucocorticoid treatment with no viable alternative is over.” Continue reading →
RA Matters is an international project aiming to explore what matters most to people living with RA. Using online crowdsourcing to invite participants, RA Matters asks questions about relationships, activities, work and aspirations, in order to reveal the most important aspects of day-to-day life. RA Matters aims to elevate a global conversation that sheds light on what those with RA really want and – ultimately – help them live the best life possible.
The latest online tool to help make your treatment decisions.
We are looking for people to participate in a study to determine the usefulness of a web-based program designed to aid people with rheumatoid arthritis in making decisions to start or switch biologics.
If you have started discussing STARTING OR SWITCHING BIOLOGICS with your doctor, we invite you to participate in this study.
You may be eligible if you:
Have a diagnosis of rheumatoid arthritis
See a rheumatologist
Have started discussing switching or starting biologic medication with your doctor
Have a valid email and internet access
This study can be completed from home or anywhere with internet access. Any information you provide will be completely confidential. An honorarium will be provided for your time.
If you would like more information, please contact Jasmina Geldman, Research Coordinator by phone at 604-207-4007, toll free 1-877-871-4575, or email firstname.lastname@example.org. Please also visit our UBC Study Website for more information.
Effects of Social Networking on Chronic Disease Management in Arthritis
Do you have rheumatoid arthritis? Sign up for the Social Networking for Arthritis Patients (SNAP) study now.
The Social Networking for Arthritis Patients (SNAP) study is funded by The Rheumatology Research Foundation, a non-profit organization dedicated to research to improve the health of people with arthritis. Throughout the study, you will be having social interactions with patient representatives from The Arthritis Foundation, The International Foundation for Autoimmune Arthritis and The Arthritis Society. You may qualify for the study if you:
Are 18 years or older
Have been diagnosed by a doctor as having rheumatoid arthritis for 10 years or less
Have an email address
Able to communicate in English
Are comfortable with using the internet
Are familiar with social media
Live in the United States of America or Canada
Your participation would be online only and you will receive compensation for your time and effort. Your expected time commitment is 6 months. The participant will be asked to access webpages and complete online questionnaires at three time points.Do you have rheumatoid arthritis? Sign up for the Social Networking for Arthritis Patients (SNAP) study now.
This study is being conducted by investigators at the University of Texas MD Anderson Cancer Center. To find out if you are eligible to participate, contact Jessica, research coordinator, at 1(713)563-8817 or email email@example.com.